Arcturus Therapeutics Holdings Stock News

Zacks Investment Research downgraded shares of Arcturus Therapeutics (NASDAQ:ARCT) from a hold rating to a sell rating in a research note issued to investors on Thursday, Zacks.com reports. According to Zacks, Arcturus Therapeutics Ltd. is a preclinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of RNA medicines using proprietary lipid-mediated delivery system []

Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q3 2021 Results - Earnings Call Transcript

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -46.43% and -90.87%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the s

Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company foc

The company disappointed last year, but things may be turning around.

Three healthcare giants are vying for the prize.

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine

The company has a specific opportunity to be a vaccine supplier within Asia and to the world.

Buying biotech stocks while they're down is rewarding once they post positive clinical results, setting the stage for a big rally. The post 7 Busted Biotech Stocks Due for a Rebound appeared first on

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

With the trading day more than halfway over, the broad markets were mixed yet again, but this came with a couple of record highs.

The stock price of Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) increased by over 35% pre-market. This is why it happened.

Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q2 2021 Results - Earnings Call Transcript